Thank you, Eva, and thank you all for joining us this morning. Before turning to our fourth quarter results, I would like to ...

Moby Strategic Pillars and Performance Drivers. Management characterizes 2025 as a foundational year of disciplined e ...

Creative Biolabs’ expanded primary neuron portfolio includes cortical, hippocampal, dopaminergic, and sensory neurons isolated and characterized under stringent quality control (QC) standards and ...

Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of ...

Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 ...

From 4L80E and Allison six-speeds to the 10R80 and Gear Vendors, these overdrive transmissions reshaped street performance, ...

Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.

Apellis Pharmaceuticals APLS reported fourth-quarter 2025 loss of 47 cents per share, wider than the Zacks Consensus Estimate ...

A team of researchers have come to the conclusion that cities are warming much faster than the surrounding countryside, the ...

A woman in her 20s with a mechanical mitral valve replacement on long-term warfarin therapy presented with frank haematuria and acute kidney injury (AKI). The initial clinical impression was ...

There are no SEC filings that match your filter(s), please update your selections to return more records. Nasdaq provides company’s SEC filings, which are financial statements and reports filed ...